Dialine s.r.o.
- Address
- Tylova 502/39, Jizni Predmesti, 301 00 Pilsen, Czechia
Nutritional and Metabolic Diseases
Dialine s.r.o. in Plzen is conducting clinical research focused on Nutritional and Metabolic Diseases, with studies centered on common conditions such as Type 2 Diabetes, Obesity, and Overweight. The trials are aimed at improving blood sugar control, supporting weight reduction, and assessing the broader impact of new treatment options on metabolic health.
- Research in Type 2 diabetes and Diabetes Type 2 is evaluating new ways to improve glycaemic control and treatment effectiveness.
- Studies in Obesity and Overweight or Obesity are testing therapies designed to reduce body weight and support long-term management.
- Cardiovascular Diseases and Chronic Kidney disease are included in trials that examine safety and potential benefits beyond metabolic control.
The site’s research activity includes comparisons of emerging treatments with established options, with a strong focus on both metabolic outcomes and cardiovascular risk.
Diabetes and Weight Management Research
Clinical trials at this Hospital/Clinic/Other health care facility are exploring therapies for Type 2 Diabetes alongside body weight-related conditions, reflecting a strong interest in the overlap between glucose control and obesity care. These studies aim to determine whether new medicines can lower blood sugar more effectively while also helping patients manage excess weight.
- Trials in Type 2 Diabetes are assessing improved glycaemic control in people already receiving standard therapy.
- Weight-focused studies are examining whether new treatments can support meaningful reductions in body weight.
- Several projects look at patients with overweight or obesity who also face elevated metabolic and cardiovascular risk.
This portfolio highlights practical research on everyday chronic disease management, with attention to both symptom control and longer-term health outcomes.
Cardiometabolic Safety and Outcomes
The clinical trial program at Dialine s.r.o. also includes studies designed to assess cardiovascular safety and major health outcomes in people with metabolic disease. Rather than focusing only on blood sugar or weight, these trials examine whether new therapies may influence serious events affecting the heart and blood vessels.
- Research in Cardiovascular Diseases evaluates whether treatment options can support safer long-term use in at-risk patients.
- Studies involving Type 2 Diabetes and obesity consider broader risks such as heart attack, stroke, and related complications.
- Some trials are intended to compare new medicines with existing treatments to better understand overall effectiveness and safety.
This makes the site a relevant center for research that connects metabolic care with cardiometabolic risk reduction.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dialine s.r.o.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2023-08-02 | 2025-05-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.